Arctigenin from Arctium lappa L. inhibits chikungunya virus by affecting its entry and replication
Phytomedicine · 2024
DOI: 10.1016/j.phymed.2024.155491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Shridhar Shukla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dengue and Chikungunya Group, ICMR-National Institute of Virology, Pune, India 411001. Hauptthemen laut MEDLINE: Antiviral Agents, Arctium, Chikungunya virus, Dengue Virus. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: ICMR- National Institute of Virology.
Abstract (Originalsprache)
BACKGROUND: Dengue and chikungunya, caused by dengue virus (DENV) and chikungunya virus (CHIKV) respectively, are the most common arthropod-borne viral diseases worldwide, for which there are no FDA-approved antivirals or effective vaccines. Arctigenin, a phenylpropanoid lignan from the seeds of Arctium lappa L. is known for its anti-inflammatory, anti-cancer, antibacterial, and immunomodulatory properties. Arctigenin's antimicrobial and immunomodulatory capabilities make it a promising candidate for investigating its potential as an anti-DENV and anti-CHIKV agent. PURPOSE: The aim of the study was to explore the anti-DENV and anti-CHIKV effects of arctigenin and identify the possible mechanisms of action. METHODS: The anti-DENV or anti-CHIKV effects of arctigenin was assessed using various in vitro and in silico approaches. Vero CCL-81 cells were infected with DENV or CHIKV and treated with arctigenin at different concentrations, temperature, and time points to ascertain the effect of the compound on virus entry or replication. In silico molecular docking was performed to identify the interactions of the compound with viral proteins. RESULTS: Arctigenin had no effects on DENV. Various time- and temperature-dependent assays revealed that arctigenin significantly reduced CHIKV RNA copy number and infectious virus particles and affected viral entry. Entry bypass assay revealed that arctigenin inhibited the initial steps of viral replication. In silico docking results revealed the high binding affinity of the compound with the E1 protein and the nsp3 macrodomain of CHIKV. CONCLUSION: This study demonstrates the in-vitro anti-CHIKV potential of arctigenin and suggests that the compound might affect CHIKV entry and replication. Further preclinical and clinical studies are needed to identify its safety and efficacy as an anti-CHIKV drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dengue and Chikungunya Group, ICMR-National Institute of Virology, Pune, India 411001.
- Dengue and Chikungunya Group, ICMR-National Institute of Virology, Pune, India 411001. Electronic address: alagarasu@gmail.com.
- Dengue and Chikungunya Group, ICMR-National Institute of Virology, Pune, India 411001. Electronic address: deeptiparasharster@gmail.com.
Förderung
- ICMR- National Institute of Virology
Zitieren
APA
Shukla, S., Kakade, M., Cherian, S., Alagarasu, K., & Parashar, D. (2024). Arctigenin from Arctium lappa L. inhibits chikungunya virus by affecting its entry and replication. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.155491
Vancouver
Shukla S, Kakade M, Cherian S, Alagarasu K, Parashar D. Arctigenin from Arctium lappa L. inhibits chikungunya virus by affecting its entry and replication. Phytomedicine. 2024. doi:10.1016/j.phymed.2024.155491
BibTeX
@article{Shukla2024,
author = {Shukla, Shridhar and Kakade, Mahadeo and Cherian, Sarah and Alagarasu, Kalichamy and Parashar, Deepti},
title = {Arctigenin from Arctium lappa L. inhibits chikungunya virus by affecting its entry and replication},
journal = {Phytomedicine},
year = {2024},
doi = {10.1016/j.phymed.2024.155491}
}
EUVIMED